Login to Your Account


Taigen Biotechnology inks licensing deal with R-Pharm, raises $36.4M in Taiwan IPO

By Shannon Ellis
Staff Writer

Wednesday, January 22, 2014

SHANGHAI – A new licensing deal is giving Taiwan’s Taigen Biotechnology Co. inroads into the large Russian market just as the parent company’s shares started trading in Taiwan.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription